nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

11.07.2020 | Original Article

Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer

verfasst von: Fang-Tao Wang, Hui Wang, Qi-Wei Wang, Mu-Su Pan, Xin-Ping Li, Wei Sun, Yue-Zu Fan

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Gemcitabine (GEM), as an anti-metabolic nucleoside analog, has been shown to have anticancer effects in various tumors, but its chemotherapy resistance is still an important factor leading to poor prognosis of cancer patient. A large number of studies in recent years have shown that autophagy plays an important role in the chemotherapy sensitivity of many tumors, including pancreatic, non-small cell lung, and bladder cancer. However, whether GEM causes autophagy in gallbladder cancer (GBC) and whether it is related to chemotherapy resistance is unknown. In the present study, we demonstrated that GEM induced apoptosis and protective autophagy in GBC cells, which may be related to the AKT/mTOR signaling pathway, and GEM in combination with autophagy inhibitor chloroquine can strengthen the cytotoxic effect of GEM on GBC in vitro and in vivo. These findings showed that both autophagy and AKT/mTOR signals were engaged in GBC cell death evoked by GEM, GBC patients might benefit from this new treatment strategy, and molecular targeted treatment in combination with autophagy inhibitors shows promise as a treatment improvement.

Nur mit Berechtigung zugänglich

Hsing AW, Sakoda LC, Rashid A, Chen J, Shen MC, Han TQ, Wang BS, Gao YT (2008) Body size and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 99(5):811–815PubMedPubMedCentral

Hsing AW, Bai Y, Andreotti G, Rashid A, Deng J, Chen JB, Goldstein AM, Han TQ, Shen MC, Fraumeni JF et al (2007) Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int J Cancer 121(4):832–838PubMedPubMedCentral

Wernberg JA, Lucarelli DD (2014) Gallbladder cancer. Surg Clin N Am 94(2):343–360PubMed

Zheng YH, Xu DY, Bu ZD (2016) Chinese version of NCCN clinical practice guidelines in oncology officially authorized by NCCN. Chin J Cancer Res 28(1):144–145PubMedPubMedCentral

Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR (2015) Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Investig New Drugs 33(4):963–968

Chen YM, Perng RP, Tsai CM, Whang-Peng J (2006) A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Lung Cancer 52(3):333–338PubMed

Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S, Li J, Wu F, Zhang H, Zhao Z, Ding S (2015) A potent chemotherapeutic strategy with Eg5 inhibitor against gemcitabine resistant bladder cancer. PLoS One 10(12):e0144484PubMedPubMedCentral

Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–1617PubMed

Valle J (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (vol 362, pg 1273, 2010). New Engl J Med 363(2):198

10.

Qu K, Liu SN, Chang HL, Liu C, Xu XS, Wang RT, Zhou L, Tian F, Wei JC, Tai MH et al (2012) Gallbladder cancer: a subtype of biliary tract cancer which is a current challenge in China. Asian Pac J Cancer Prev 13(4):1317–1320PubMed

11.

Hirooka Y, Ishikawa T, Kawashima H, Ohno E, Nonogaki K, Kanamori A, Hirai T, Uchida H, Shirai O, Ishikawa H et al (2017) Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer. Cancer Chemother Pharmacol 80(1):119–125PubMed

12.

Iyer Renuka V, Pokuri Venkata K, Adrienne Groman et al (2018) A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol 41:649–655PubMed

13.

Moehler M, Maderer A, Schimanski C et al (2014) Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer 50:3125–3135PubMed

14.

Siebenhüner Alexander R, Heike Seifert, Helga Bachmann et al (2018) Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer 18:72PubMedPubMedCentral

15.

White E (2015) The role for autophagy in cancer. J Clin Investig 125(1):42–46PubMed

16.

Zhang XF, Zhao P, Wang CH, Xin BR (2019) SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. Biochem Biophys Res Commun 510(4):508–514PubMed

17.

Xiong JJ, Wang D, Wei AL, Ke NW, Wang YC, Tang J, He SR, Hu WM, Liu XB (2017) MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Oncotarget 8(64):107500–107512PubMedPubMedCentral

18.

Li CG, Zhao ZM, Zhou ZP, Liu R (2016) Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. Cancer Chemother Pharmacol 78(6):1199–1207PubMed

19.

Song B, Bian Q, Zhang YJ, Shao CH, Li G, Liu AA, Jing W, Liu R, Zhou YQ, Jin G et al (2015) Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol Cancer 14:177PubMedPubMedCentral

20.

Ma T, Chen W, Zhi X, Liu H, Zhou Y, Chen BW, Hu LQ, Shen J, Zheng XX, Zhang SF et al (2018) USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Cancer Lett 436:129–138PubMed

21.

Kaur S, Bafna S, Rachagani S, Ganti AK, Batra SK (2012) Mucin MUC4 resists gemcitabine-induced pancreatic cancer cell death by promoting autophagy. Pancreas 41(8):1374–1375

22.

Zhu JH, Chen Y, Ji Y, Yu YQ, Jin Y, Zhang XX, Zhou JL (2018) Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells. Biotechnol Appl Biochem 65(5):665–671PubMed

23.

Wu HM, Shao LJ, Jiang ZF, Liu RY (2016) Gemcitabine-induced autophagy protects human lung cancer cells from apoptotic death. Lung 194(6):959–966PubMed

24.

Chen M, He MY, Song YJ, Chen LQ, Xiao P, Wan XP, Dai F, Shen P (2014) The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. Int J Mol Med 34(1):276–282PubMed

25.

Sui X, Chen R, Wang Z et al (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e828

26.

Donohue E, Thomas A, Maurer N, Manisali I, Zeisser-Labouebe M, Zisman N, Anderson HJ, Ng SSW, Webb M, Bally M et al (2013) The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer 4(7):585–596PubMedPubMedCentral

27.

Yin L, Liu S, Li CS, Ding ST, Bi DB, Niu ZH, Han LP, Li WJ, Gao DX, Liu Z et al (2016) CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated. Tumor Biol 37(9):12731–12742

28.

Fu Z, Cheng X, Kuang J, Feng H, Chen L, Liang J, Shen X, Yuen S, Peng C, Shen B et al (2018) CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species. Mol Oncol 12(4):529–544PubMedPubMedCentral

29.

Papademetrio DL, Cavaliere V, Simunovich T, Costantino S, Campos MD, Lombardo T, Kaiser CMF, Alvarez E (2014) Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. Target Oncol 9(2):123–134PubMed

30.

Li XS, Yan J, Wang LS, Xiao FJ, Yang YF, Guo XZ, Wang H (2013) Beclin1 inhibition promotes autophagy and decreases gemcitabine-induced apoptosis in Miapaca2 pancreatic cancer cells. Cancer Cell Int 13:26PubMedPubMedCentral

31.

Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T (2009) Monitoring autophagic degradation of P62/Sqstm1. Methods Enzymol Autophagy Mamm Syst 452(Pt B):181–197

32.

Hasanain M, Bhattacharjee A, Pandey P, Ashraf R, Singh N, Sharma S, Vishwakarma AL, Datta D, Mitra K, Sarkar J (2015) Alpha-solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt/mTOR pathway. Cell Death Dis 6:e1860PubMedPubMedCentral

33.

Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14(11):2201–2214PubMed

34.

Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease (vol 168, pg 960, 2017). Cell 169(2):362

35.

Nicholson KM, Anderson NG (2012) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381–395

36.

Majumder PK, Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24:7465–7474PubMed

37.

Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T et al (2015) Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. Int J Oncol 47(4):1293–1302PubMed

38.

Kilani R, Tamimi Y, Karmali S, Mackey J, Hanel E, Wong KK, Moore RB (2002) Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs 13(6):557–566PubMed

39.

Kang YW, Lee JE, Jung KH, Son MK, Shin SM, Kim SJ, Fang ZH, Yan HH, Park JH, Han B et al (2018) KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Cancer Lett 438:174–186PubMed

40.

Teng JP, Yang ZY, Zhu YM, Ni D, Zhu ZJ, Li XQ (2018) Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo. Eur Rev Med Pharmacol Sci 22(12):3819–3825PubMed

41.

Tsuchihara K, Fujii S, Esumi H (2009) Autophagy and cancer: dynamism of the metabolism of tumor cells and tissues. Cancer Lett 278(2):130–138PubMed

42.

Du HL, Yang WP, Chen L, Shi MM, Seewoo V, Wang JY, Lin AD, Liu ZR, Qiu WH (2012) Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells. Oncol Rep 27(1):143–150PubMed

43.

Pardo R, Lo Re A, Archange C, Ropolo A, Papademetrio DL, Gonzalez CD, Alvarez EM, Iovanna JL, Vaccaro MI (2010) Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells. Pancreatology 10(1):19–26PubMed

44.

Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen GH, Mukherjee C, Shi YF, Gelinas C, Fan YJ et al (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10(1):51–64PubMedPubMedCentral

45.

Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14(3):500–510PubMed

46.

Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A et al (2015) Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101). BMC Cancer 15:224PubMedPubMedCentral

47.

Ojha R, Jha V, Singh SK (2016) Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells. Biochim Biophys Acta-Mol Cell Res 1863(2):347–359

48.

Tavassoly I, Parmar J, Shajahan-Haq AN, Clarke R, Baumann WT, Tyson JJ (2015) Dynamic modeling of the interaction between autophagy and apoptosis in mammalian cells. Cpt-Pharmacomet Syst Pharmacol 4(4):263–272

49.

Mukhopadhyay S, Panda PK, Sinha N, Das DN, Bhutia SK (2014) Autophagy and apoptosis: where do they meet? Apoptosis 19(4):555–566PubMed

50.

Moretti L, Cha YI, Niermann KJ, Lu B (2007) Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress? Cell Cycle 6(7):793–798PubMed

51.

Jiang Q, Li F, Shi K, Wu P, An J, Yang Y, Xu C (2014) Involvement of p38 in signal switching from autophagy to apoptosis via the PERK/eIF2 alpha/ATF4 axis in selenite-treated NB4 cells. Cell Death Dis 5:e1270PubMedPubMedCentral

52.

Dang SP, Yu ZM, Zhang CY, Zheng J, Li KL, Wu Y, Qian LL, Yang ZY, Li XR, Zhang YY et al (2015) Autophagy promotes apoptosis of mesenchymal stem cells under inflammatory microenvironment. Stem Cell Res Ther 6:247PubMedPubMedCentral

53.

Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA et al (2015) Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol 22(13):4402–4410PubMedPubMedCentral

54.

Jiang YF, Han ZD, Wang Y, Hao WB (2018) Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy. Biochem Biophys Res Commun 506(1):266–271PubMed

55.

Chen Y-M, Liu Y, Wei H-Y, Lv K-Z, Fu P-F (2016) Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells. Oncotarget 7(37):59604–59617PubMedPubMedCentral

56.

Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411(6835):355–365PubMed

57.

Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21(43):6587–6597PubMed

58.

LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11(1–2):32–50PubMed

59.

Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, Shen HM, Zeng HT (2007) Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 28(11):1819–1826PubMed

60.

Liu Y, Chen ZJ, Cheng HX, Chen J, Qian J (2017) Gremlin promotes retinal pigmentation epithelial (RPE) cell proliferation, migration and VEGF production via activating VEGFR2-Akt-mTORC2 signaling. Oncotarget 8(1):979–987PubMed

61.

Yang MH, Lee KT, Yang S, Lee JK, Lee KH, Moon IH, Rhee JC (2012) Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-kappa B. J Cancer Res Clin Oncol 138(10):1743–1751PubMed

Titel: Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer
verfasst von: Fang-Tao Wang
Hui Wang
Qi-Wei Wang
Mu-Su Pan
Xin-Ping Li
Wei Sun
Yue-Zu Fan
Publikationsdatum: 11.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2020
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-020-04100-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration

A phase Ι study to evaluate the application of photocyanine using pharmacokinetic and pharmacodynamic analysis in patients with malignancy

Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer

Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects

A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)

A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie